


I. Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application.

Claims 1-55 (canceled)

56. (Currently Amended) ~~The compound of Claim 53, which is a A~~ compound of formula XX:



wherein

Q' is methylene;

each X is independently -O- or -NH-;


each R¹ is independently methyl or chloro;


each R² is independently 1,2-ethylene, 1,3-propylene, (2R)-2-(methyl)ethane-1,2-diyl, (2S)-2-(methyl)ethane-1,2-diyl, 1-(methyl)butane-1,4-diyl, 1-(methyl)ethane-1,2-diyl, or 2,2-(dimethyl)propane-1,3-diyl;

each Y is -NH₂;

or a pharmaceutically-acceptable salt thereof.

57. (Currently Amended) The compound of Claim 56, which is any one of compounds 27, and 28, 29, 30, 31, 36, and 37:





or a pharmaceutically acceptable salt thereof.

Claims 58-61 (canceled)

62. (Currently Amended) A pharmaceutical composition comprising a therapeutically effective amount of a compound as described in Claim 40 Claim 56 and a pharmaceutically acceptable carrier.

63. (Currently Amended) A method of treating a disease or condition associated with sodium channel activity in a mammal, comprising administering to the mammal, a

therapeutically effective amount of a pharmaceutical composition comprising a compound as described in ~~Claim 40~~ Claim 56 and a pharmaceutically acceptable carrier.

64. (Previously Presented) The method of Claim 63 wherein the disease or condition is neuropathic pain.